Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

Clarisse Dromain.,Marianne Pavel,Philippe Ruszniewski,Alison Langley,Christine Massien,Éric Baudin,Martyn Caplin

Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

2019

Clarisse Dromain.
Marianne Pavel
Philippe Ruszniewski
Alison Langley
Christine Massien
Éric Baudin
Martyn Caplin

Background Lanreotide depot/autogel antitumor activity in intestinal/pancreatic neuroendocrine tumors (NETs) was demonstrated in the phase-3 CLARINET study (NCT00353496), based on significantly prolonged progression-free survival (PFS) versus placebo.

Keywords:

Placebo
Oncology
Cancer research
Lanreotide
Medicine
Neuroendocrine tumors
Internal medicine
tumor growth
Surgical oncology
Proportional hazards model
antitumor activity
prognostic factor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations